Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Journal: American journal of hematology
Published: December 20, 2018
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 04, 2018
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Journal: Haematologica
Published: November 09, 2014
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Journal: British journal of haematology
Published: July 10, 2014
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 16, 2014
Showing 1-6 of 6
Last Updated: 09/26/2026